| Article ID | Journal | Published Year | Pages | File Type |
|---|---|---|---|---|
| 4126349 | Otolaryngology - Head and Neck Surgery | 2008 | 7 Pages |
Abstract
PPAR-γ activation with rosiglitazone effectively inhibited allergic symptom development, nasal mucosal inflammation, and production of ovoalbumin-specific immunoglobulin E and Th2-type cytokine. Our results provide evidence of the therapeutic potential of PPAR-γ agonist for the treatment of allergic rhinitis.
Related Topics
Health Sciences
Medicine and Dentistry
Otorhinolaryngology and Facial Plastic Surgery
Authors
Eun-Ju MD, Seung Kyun MD, Yong-Soo MD, Dong-Hyun MD, Jin Ho MD, Chan-Soon MD,